Ardent Health Faces Class Action Over $43M Revenue Drop, Shares Plunge 34%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 18h ago
0mins
Source: Businesswire
- Lawsuit Reminder: Kahn Swick & Foti LLC alerts investors who purchased Ardent securities between July 18, 2024, and November 12, 2025, to file lead plaintiff applications by March 9, 2026, to seek recovery for economic losses incurred during this period.
- Revenue Decline Disclosure: On November 12, 2025, Ardent revealed a $43 million drop in Q3 revenue due to adjustments from a new revenue accounting system and evaluations of historical collection trends, significantly undermining market confidence in the company's financial health.
- EBITDA Guidance Cut: The company revised its 2025 EBITDA guidance down to $530 million to $555 million, a reduction of approximately 9.6% from the previous range of $575 million to $625 million, reflecting persistent industry-wide cost pressures and payer denials, which may further erode investor confidence.
- Stock Price Plunge: Following the revenue drop announcement, Ardent's stock price plummeted from $14.05 to $9.30 per share, a nearly 34% decline, indicating extreme investor concern regarding the company's future outlook.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDT is 13.96 USD with a low forecast of 10.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 9.210
Low
10.00
Averages
13.96
High
17.00
Current: 9.210
Low
10.00
Averages
13.96
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
